Study directory

Mental health studies with practical context.

Compare studies and check their requirements with the research team.

Back to overview

25901studies shown

Showing 229-240 of 25,901

Drug study icon

RecruitingNCT07140913

KarXT for manic episodes in bipolarity type I

The registry lists this study as recruiting. Study locations are listed in the United States, in France, in Argentina, ...

Multiple locations, including Bentonville

BipolarityDrugFrom 18 Years to 65 Years

Countries: United States, France, Argentina, ...
Sponsor: Bristol-Myers Squibb
Condition: Bipolarity

Drug study icon

RecruitingNCT07227454

Esketamine for depression

The registry lists this study as recruiting. Study locations are listed in the United States, in Brazil, in Hungary, ...

Multiple locations, including Birmingham

DepressionDrugFrom 12 Years to 17 Years

Countries: United States, Brazil, Hungary, ...
Sponsor: Janssen Research & Development, LLC
Condition: Depression

Drug study icon

RecruitingNCT06951698

KarXT for manic episodes in bipolarity type I

The registry lists this study as recruiting. Study locations are listed in the United States, in Australia, in New Zealand, ...

Multiple locations, including Little Rock

BipolarityDrugFrom 18 Years to 65 Years

Countries: United States, Australia, New Zealand, ...
Sponsor: Bristol-Myers Squibb
Condition: Bipolarity

Drug study icon

RecruitingNCT06951711

KarXT for manic episodes in bipolarity type I

The registry lists this study as recruiting. Study locations are listed in the United States, in China, in Croatia, ...

Multiple locations, including Little Rock

BipolarityDrugFrom 18 Years to 65 Years

Countries: United States, China, Croatia, ...
Sponsor: Bristol-Myers Squibb
Condition: Bipolarity

Drug study icon

RecruitingNCT07288567

KarXT for schizophrenia

The registry lists this study as recruiting. Study locations are listed in the United States, in Colombia, in Japan, ...

Multiple locations, including Anaheim

SchizophreniaDrugFrom 13 Years to 17 Years

Countries: United States, Colombia, Japan, ...
Sponsor: Bristol-Myers Squibb
Condition: Schizophrenia

Drug study icon

RecruitingNCT06882785

KarXT for schizophrenia

The registry lists this study as recruiting. Study locations are listed in Japan.

Multiple locations, including Kōnan

SchizophreniaDrugFrom 18 Years to 65 Years

Countries: Japan
Sponsor: Bristol-Myers Squibb
Condition: Schizophrenia

Drug study icon

RecruitingNCT07065240

SPT-300 (GlyphAllo) for depression

The registry lists this study as recruiting. Study locations are listed in the United States, in Bulgaria, in Czechia, ...

Multiple locations, including Chino

DepressionDrugFrom 18 Years to 65 Years

Countries: United States, Bulgaria, Czechia, ...
Sponsor: Seaport Therapeutics
Condition: Depression

Drug study icon

RecruitingNCT06223880

Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

The registry lists this study as recruiting. Study locations are listed in the United States.

Multiple locations, including Bellflower

DepressionDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: Axsome Therapeutics, Inc.
Condition: Depression

Drug study icon

RecruitingNCT07424404

KarXT and KarX-EC for schizophrenia

The registry lists this study as recruiting. Study locations are listed in the United States, in Australia, in France, ...

Multiple locations, including Anaheim

SchizophreniaDrugFrom 5 Years to 17 Years

Countries: United States, Australia, France, ...
Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition: Schizophrenia

Drug study icon

RecruitingNCT07196501

Maintenance Effect of NBI-1065845 for depression

The registry lists this study as recruiting. Study locations are listed in the United States, in Australia, in Canada, ...

Multiple locations, including Oceanside

DepressionDrugOver 18 Years

Countries: United States, Australia, Canada, ...
Sponsor: Neurocrine Biosciences
Condition: Depression

Drug study icon

RecruitingNCT07061288

Safety, Tolerability, and PK of an Injectable Form of KarXT

The registry lists this study as recruiting. Study locations are listed in the United States.

Multiple locations, including Los Alamitos

SchizophreniaDrugFrom 18 Years to 55 Years

Countries: United States
Sponsor: Bristol-Myers Squibb
Condition: Schizophrenia

Drug study icon

RecruitingNCT07621237

TNX-102 SL Monotherapy Versus Placebo in people with Major Depressive Disorder (MDD)

The registry lists this study as recruiting. Study locations are listed in the United States.

Multiple locations, including Orlando

DepressionDrugOver 18 Years

Countries: United States
Sponsor: Tonix Pharmaceuticals, Inc.
Condition: Depression

Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.